Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease.
Journal
Ophthalmic plastic and reconstructive surgery
ISSN: 1537-2677
Titre abrégé: Ophthalmic Plast Reconstr Surg
Pays: United States
ID NLM: 8508431
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
This study evaluates the efficacy of teprotumumab in reducing eyelid retraction in thyroid eye disease (TED) patients. This retrospective study included patients with active or chronic moderate-to-severe TED who completed at least 4 cycles of teprotumumab. Patients with upper and/or lower eyelid retraction, defined as margin-to-reflex distance (MRD) 1 and/or MRD2 of more than 5 mm, in one or OU were included. The main outcome measure was a change in MRD1 and MRD2 after treatment. Changes in MRD1 and MRD2 were each analyzed for correlation (r) with changes in exophthalmolmetry. Student t test was performed for each comparison, and p values <0.05 were considered significant. The study included 91 patients, predominantly female (87%), with an average age of 52.02 ± 14.6 years. The mean baseline proptosis measurement was 21.8 ± 2.9 OD and 21.7 ± 3.3 OS. The average MRD1 was 5.5 ± 1.5 OD and 5.4 ± 1.7 OS, and the average MRD2 was 6.1 ± 1.1 OD and 6.2 ± 1.1 OS. The follow-up duration post-treatment was 37.5 ± 31.7 weeks. At first follow-up post-treatment, the mean change in proptosis, MRD1, and MRD2 were -2.6 ± 2.0 OD, -2.5 ± 2.1 OS, -0.8.5 ± 1.4 OD, -0.8 ± 1.0 OS, and -0.7 ± 0.9 OD, -0.8 ± 1.0 OS, respectively. Correlation analysis showed that proptosis reduction was positively correlated with MRD1 and MRD2 reduction at the first post-treatment follow-up (MRD1: r = 0.23, p value < 0.01; MRD2: r = 0.17, p = 0.03]. Teprotumumab treatment improves upper and lower eyelid retraction. The improvement in MRD correlated positively with proptosis reduction, indicating the influence of globe position on eyelid position.
Identifiants
pubmed: 38722772
doi: 10.1097/IOP.0000000000002707
pii: 00002341-990000000-00395
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.
Déclaration de conflit d'intérêts
D.O.K.: Consultant: Horizon Therapeutics, Lassen Therapeutics, Thyroscope, Immunovant. B.S.K.: Consultant: Horizon Therapeutics, Immunovant, Elsevier Royalties. C.Y.L.: Site principal investigator for phase IV clinical trial- Horizon Therapeutics; Wolters Kluwers Health Royalties. Other authors have no financial or conflicts of interest to disclose.
Références
Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med 2016;375:1552–1565.
Rundle F, Wilson C. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 1945;5:177–194.
Park JJ, Sullivan TJ, Mortimer RH, et al. Assessing quality of life in Australian patients with Graves’ ophthalmopathy. Br J Ophthalmol 2004;88:75–78.
Wickwar S, McBain HB, Ezra DG, et al. What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review. Thyroid 2014;24:1407–1418.
Ponto KA, Hommel G, Pitz S, et al. Quality of life in a German graves orbitopathy population. Am J Ophthalmol 2011;152:483–490.e1.
Ferløv-Schwensen C, Brix TH, Hegedüs L. Death by suicide in Graves’ disease and Graves’ orbitopathy: a nationwide Danish register study. Thyroid 2017;27:1475–1480.
Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284–290.
Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477–588.
Osaki T, Monteiro L, Osaki M. Management of eyelid retraction related to thyroid eye disease. Taiwan J Ophthalmol 2022;12:12–21.
Strianese D. Efficacy and safety of immunosuppressive agents for thyroid eye disease. Ophthalmic Plast Reconstr Surg 2018;34(4S Suppl 1):S56–S59.
Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol 2017;28:505–513.
Bartalena L, Krassas GE, Wiersinga W, et al.; European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active graves’ orbitopathy. J Clin Endocrinol Metab 2012;97:4454–4463.
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020;382:341–352.
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 2017;376:1748–1761.
Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor i receptor pathway. J Immunol 2003;170:6348–6354.
Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like growth factor-1 Receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol 2007;178:3281–3287.
Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008;181:5768–5774.
Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment. Ophthalmology 2022;129:438–449.
Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 2021;9:360–372.
Ting MA, Ozzello DJ, Topilow NJ, et al. Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease. Orbit 2023;42:418–425.
Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit 2022;41:539–546.
Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep 2020;19:100744.
Simmons BA, Tran C, Pham CM, et al. The effect of teprotumumab on eyelid position in patients with thyroid eye disease. Plast Reconstr Surg Glob Open 2022;10:e4287.
Ugradar S, Braun J, Wang Y, et al. Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Glob Open 2021;9:e3809.
Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond) 2022;36:1553–1559.
Ugradar S, Zimmerman E, Parunakian E, et al. Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clin Experiment Ophthalmol 2023;51:339–348.
Chu M, Sung J, Song M, et al. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series. J Med Case Rep 2022;16:195.
Rosenblatt TR, Chiou CA, Yoon MK, et al. Change in upper eyelid position after teprotumumab treatment for thyroid eye disease. Orbit. 2024;11:1–7.
Dutton JJ. Anatomic considerations in thyroid eye disease. considerations in thyroid eye disease. Ophthalmic Plast Reconstr Surg 2018;34:S7–S12.
Lemke B. Anatomic considerations in upper eyelid retraction. Plast Reconstr Surg 1991;7:158–166.
Bartley GB. The differential diagnosis and classification of eyelid retraction. Ophthalmology 1996;103:168–176.
Rajabi MT, Jafari H, Mazloumi M, et al. Lower lid retraction in thyroid orbitopathy: lamellar shortening or proptosis? Int Ophthalmol 2014;34:801–804.
Rosenblatt TR, Chiou CA, Yoon MK, et al. Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg 2024;40:187–191.